Previous 10 | Next 10 |
Palm Beach, FL –December 9, 2020 – In the breast cancer therapy market, the rise in the healthcare awareness among individual’s disease and treatment, early detection of the cancer, better surgical and medical treatment, R&D initiatives, and technological advancemen...
Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%....
Biotech Penny Stocks To Watch Before The New Year This week was more than just a big week for penny stocks . Several sectors and broader markets in general, reached new all-time highs. Now, not only did we see things like the S&P and Dow mirror that, but we also saw the Russell ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) surges +38.2% in pre-market trading after Citi raised its rating from Neutral to Buy.Amid collaboration chatter, the stock “should regain momentum” noted the analyst Yigal Nochomovitz as partnership talks continue after an exp...
Curis CRIS +199% on encouraging CA-4948 data in leukemia.NeuroMetrix (NURO) +84%.Stitch Fix SFIX +39% on Q1 results.Lexicon Pharmaceuticals (LXRX) +31%.Cancer Genetics (CGIX) +28%.Smartsheet SMAR +18% on Q3 results.Tarena TEDU +18% on founder's going pr...
Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Se...
Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) ...
Lexicon Pharmaceuticals (LXRX) +49% after its drug shows benefits for heart patients.Yunhong CTI (CTIB) +43%.Mogo (MOGO) +42% after entering agreement to acquire Carta Worldwide.Sequential Brands Group (SQBG) +36% on Q3 results.Golden Bull Limited (BTBT) +19%.Com...
Lexicon Pharmaceuticals (LXRX) soars as much as 80% pre-market after saying two Phase 3 studies achieved their primary endpoints by showing statistically significant reductions in cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated wit...
THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular death...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...